S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

DiaMedica Therapeutics Stock Forecast, Price & News

-0.02 (-0.59%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
72,894 shs
Average Volume
88,260 shs
Market Capitalization
$63.50 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive DMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DiaMedica Therapeutics logo

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.


DiaMedica Therapeutics appoints chief medical officer
January 5, 2022 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$1.39 per share


Net Income
$-12.29 million
Pretax Margin




Free Float
Market Cap
$63.50 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.69 out of 5 stars

Medical Sector

759th out of 1,405 stocks

Pharmaceutical Preparations Industry

364th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

Is DiaMedica Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DiaMedica Therapeutics stock.
View analyst ratings for DiaMedica Therapeutics
or view top-rated stocks.

How has DiaMedica Therapeutics' stock been impacted by Coronavirus (COVID-19)?

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DMAC stock has decreased by 15.5% and is now trading at $3.38.
View which stocks have been most impacted by COVID-19

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a decline in short interest in December. As of December 31st, there was short interest totaling 61,500 shares, a decline of 22.4% from the December 15th total of 79,300 shares. Based on an average trading volume of 161,700 shares, the short-interest ratio is presently 0.4 days. Currently, 0.3% of the shares of the stock are sold short.
View DiaMedica Therapeutics' Short Interest

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for DiaMedica Therapeutics

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced its earnings results on Wednesday, November, 10th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. During the same period last year, the company earned ($0.19) EPS.
View DiaMedica Therapeutics' earnings history

What price target have analysts set for DMAC?

3 brokerages have issued 12 month target prices for DiaMedica Therapeutics' stock. Their forecasts range from $11.00 to $27.00. On average, they anticipate DiaMedica Therapeutics' share price to reach $20.50 in the next year. This suggests a possible upside of 506.5% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Rick John Pauls, President. Chief Executive Officer & Director
  • Scott Kellen, Chief Financial Officer & Secretary
  • Harry W. Alcorn, Chief Medical Officer & VP-Clinical Affairs (LinkedIn Profile)
  • Sydney A. Gilman, Vice President-Regulatory Affairs

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $3.38.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics has a market capitalization of $63.50 million. The company earns $-12.29 million in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does DiaMedica Therapeutics have?

DiaMedica Therapeutics employs 11 workers across the globe.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

Where are DiaMedica Therapeutics' headquarters?

DiaMedica Therapeutics is headquartered at 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at (763) 312-6755 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.